Submitted by Anonymous (not verified) on 30 October 2023 - 14:11
Human medicines European public assessment report (EPAR): Yescarta, axicabtagene ciloleucel, Lymphoma, Follicular;Lymphoma, Large B-Cell, Diffuse, Date of authorisation: 23/08/2018, Revision: 12, Status: Authorised
Source: